TY - JOUR AB - the present retrospective study was performed to evaluate the clinicopathological characteristics associated with distant metastasis from non‑small‑cell lung cancer (NSCLC). The records of NSCLC patients with metastasis at the time of diagnosis between 1999 and 2012 were reviewed. Of the consecutive 1,542 NSCLC patients diagnosed during the study period, 729 (47.3%) patients presented with distant metastasis. Among those 729 metastatic NSCLC patients, 250 (34.3%), 234 (32.1%), 207 (28.4%), 122 (16.7%), 98 (13.4%) and 69 (9.5%) had bone, lung, brain, adrenal gland, liver and extrathoracic lymph node metastasis, respectively. In a multivariate analysis using the Cox proportional hazards model, liver and adrenal gland metastases were unfavorable prognostic factors. However, brain and bone metastases were not statistically significant prognostic factors. Using a logistic regression analysis, metastasis to the adrenal glands and the presence of pleural and̸or pericardial fluid effusion were correlated with a poor performance status. Therefore, when planning the treatment of NSCLC patients, particularly those with liver and adrenal gland metastases, we should take into consideration information regarding these unfavorable organ metastases. AD - Division of Respiratory Medicine, Institute of Clinical Medicine, University of Tsukuba, Mito, Ibaraki, Japan Division of Respiratory Medicine, Tsukuba Medical Center Hospital, Mito, Ibaraki, Japan Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Ibaraki, Japan AU - Tamura,Tomohiro AU - Kurishima,Koichi AU - Nakazawa,Kensuke AU - Kagohashi,Katsunori AU - Ishikawa,Hiroichi AU - Satoh,Hiroaki AU - Hizawa,Nobuyuki DA - 2015/01/01 DO - 10.3892/mco.2014.410 EP - 221 IS - 1 JO - Mol Clin Oncol KW - non‑small‑cell lung cancer metastasis survival PY - 2015 SN - 2049-9450 2049-9469 SP - 217 ST - Specific organ metastases and survival in metastatic non‑small‑cell lung cancer T2 - Molecular and Clinical Oncology TI - Specific organ metastases and survival in metastatic non‑small‑cell lung cancer UR - https://doi.org/10.3892/mco.2014.410 VL - 3 ER -